[CD4 TIL (Tumor Infiltrating Lymphocytes) induce complete response in patients treated with IL-2 (Interleukin-2). Preliminary study].
This study analyzed clinical response induced by TIL in patients with renal cell carcinoma previously treated by interleukin-2. Six patients (4 men, 2 women, mean age 44.3 years) with measurable metastatic localizations have been treated by TIL reinjection (0.02 to 7.6 x 10(10) cells). TIL phenotype was a combination of CD4 and CD8 in 3 patients, predominantly CD4 in two patients and predominantly CD8 in one patient. Previous treatment by interleukin-2 induced one partial response, 2 stabilizations of the disease and 3 tumoral progressions. TIL led to an amelioration for 4 patients: 2 were in complete response, 2 were stabilized and 2 had tumoral progression and decreased. This study shows that CD4 TIL may improve an initially response induced by IL-2 therapy.
Thiounn
N
N
Clinique Urologique, Hôpital Cochin, Paris.
Mathiot
C
C
Flam
T
T
Tartour
E
E
Peyret
C
C
Joyeux
I
I
Abecassis
J P
JP
Zerbib
M
M
Fridman
W H
WH
Debré
B
B
D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000637:transplantation*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D008175:Lung Neoplasms / Q000556:secondary; D016246:Lymphocytes, Tumor-Infiltrating / Q000637:transplantation*; D008297:Male; D008479:Mediastinal Neoplasms / Q000556:secondary; D008875:Middle Aged; D012186:Retroperitoneal Neoplasms / Q000556:secondary
D007376:Interleukin-2
Les TIL (Tumor Infiltrating Lymphocytes) CD4 induisent des résponses complètes chez des patients traités par IL-2 (Interleukin-2). Etude préliminaire.